Such putative differences in the distribution of amyloid pathology have not been found to alter levels of the core cerebrospinal fluid (CSF) biomarkers for AD; amyloid beta 1–42 (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau) protein, in early- compared to late-onset AD (Bouwman et al., 2009; Chiaravalloti et al., 2016). The gene discussed is MAPT; the disease is Alzheimer disease.